Approach to the Treatment of Heart Failure With Preserved Ejection Fraction and Mid- Range Ejection Fraction

In this article we discuss the treatment of heart failure (HF) with preserved ejection fraction (HFpEF) and of HF with mid-range ejection fraction (HFmrEF) as has received considerable interest since the publciation of the 2016 European Society of Cardiology (ESC) heart failure guidelines. Since clinical trials on HFpEF have included also patients with HFmrEF, due to the lack of an agreed definition, the ESC recommendations here described apply to both phenotypes. As a consequence of the recent characterisation of this HF syndrome, it is expected that upcoming research will provide data specifically regarding HFmrEF and tailored recommendations will be developed in the future.

[1]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[2]  N. Ohte,et al.  Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials , 2016, European journal of preventive cardiology.

[3]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[4]  H. Krum,et al.  Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy , 2015, The Lancet.

[5]  A. Coats,et al.  Requirements for Ethical Publishing in Biomedical Journals. , 2015 .

[6]  Deepak L. Bhatt,et al.  Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. , 2015, The lancet. Diabetes & endocrinology.

[7]  P. Kolh,et al.  2014 ESC/EACTS guidelines on myocardial revascularization. , 2015, Revista espanola de cardiologia.

[8]  Giuseppe Ambrosio,et al.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.

[9]  P. Kolh,et al.  [2014 ESC/EACTS Guidelines on myocardial revascularization]. , 2014, Kardiologia polska.

[10]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[11]  P. Ponikowski,et al.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.

[12]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[13]  S. Miyata,et al.  Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design. , 2013, Journal of cardiology.

[14]  I. V. Van Gelder,et al.  Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS , 2012, European journal of heart failure.

[15]  S. Fröhling,et al.  Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. , 2011, Journal of the American College of Cardiology.

[16]  J. Fang,et al.  Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? , 2011, Mayo Clinic proceedings.

[17]  A. Cohen-Solal,et al.  β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure , 2010, Heart.

[18]  A. Cohen-Solal,et al.  Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). , 2009, Journal of the American College of Cardiology.

[19]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[20]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[21]  G. Lamas,et al.  Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM , 2007, European journal of heart failure.

[22]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[23]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[24]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[25]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[26]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[27]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[28]  P. Poole‐Wilson,et al.  Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. , 2002, International journal of cardiology.